ArticleBMC rheumatology2024

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.

Alexis Ogdie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.